efgartigimod alfa (Vyvgart™)

Policy #  00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider efgartigimod alfa (Vyvgart™)‡ for the treatment of myasthenia gravis to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for efgartigimod alfa (Vyvgart) for the treatment of myasthenia gravis will be considered when the following criteria are met:

- Initial
  - Patient is greater than or equal to 18 years of age; AND
  - Patient has a diagnosis of generalized myasthenia gravis; AND
  - Patient has an anti-acetylcholine receptor autoantibody positive serologic test; AND
  - Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV; AND
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
  - Patient has a baseline IgG level of at least 6 g/L; AND
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
  - Patient has received or is currently receiving pyridostigmine unless there is clinical evidence or patient history that suggests the use of pyridostigmine will cause an adverse effect or inadequate response to the patient; AND
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
efgartigimod alfa (Vyvgart™)

Policy #  00790
Original Effective Date:  09/12/2022
Current Effective Date:  09/12/2022

- Patient has received or is currently receiving at least one nonsteroidal immunosuppressive therapy (NSIST) for at least 1 year unless there is clinical evidence or patient history that suggests NSISTs will be ineffective or cause an adverse reaction to the patient. Examples of NSISTs include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus, and cyclophosphamide; AND
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Patient has evidence of unresolved symptoms of generalized myasthenia gravis, such as difficulty swallowing, difficulty breathing, or a functional disability resulting in the discontinuation of physical activity (e.g., double vision, talking, impairment of mobility); AND
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Dose does not exceed the lower of 10 mg/kg or 1200 mg once weekly

Continuation
- Patient has received an initial authorization for Vyvgart; AND
- It has been at least 50 days since the start of the previous treatment cycle; AND
- Patient has experienced improvement on therapy as evidenced by at least ONE of the following
  - Improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score; OR
  - Improvement in Quantitative Myasthenia Gravis (QMG) total score; AND
    (Note: These specific patient criteria are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met.)
- Dose does not exceed the lower of 10 mg/kg or 1200 mg once weekly

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of efgartigimod alfa (Vyvgart) for myasthenia gravis that is not MGFA class II to IV, when the patient does not have a baseline IgG level of at least 6 g/dL, has not tried and failed pyridostigmine in addition to at least one NSIST, or does not have evidence of unresolved symptoms of generalized myasthenia gravis to be not medically necessary.**
efgartigimod alfa (Vyvgart™)

Policy #  00790
Original Effective Date:  09/12/2022
Current Effective Date:  09/12/2022

Based on review of available data, the Company considers the continued use of efgartigimod alfa (Vyvgart) when the patient has not experienced improvement while on therapy to be **not medically necessary.**

**When Services Are Considered Investigational**

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of efgartigimod alfa (Vyvgart) when the patient selection criteria are not met (except those denoted above as **not medically necessary**) to be investigational.*

**Policy Guidelines**

**Myasthenia Gravis Foundation of America (MGFA) Clinical Classification**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal</td>
</tr>
<tr>
<td>IIa</td>
<td>Mild weakness affecting muscles other than ocular muscles. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles</td>
</tr>
<tr>
<td>IIb</td>
<td>Mild weakness affecting muscles other than ocular muscles. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.</td>
</tr>
<tr>
<td>IIIa</td>
<td>Moderate weakness affecting muscles other than ocular muscles. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.</td>
</tr>
<tr>
<td>IIIb</td>
<td>Moderate weakness affecting muscles other than ocular muscles. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.</td>
</tr>
<tr>
<td>IVa</td>
<td>Severe weakness affecting muscles other than ocular muscles. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.</td>
</tr>
<tr>
<td>IVb</td>
<td>Severe weakness affecting muscles other than ocular muscles. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.</td>
</tr>
</tbody>
</table>
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

<table>
<thead>
<tr>
<th>Grade</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Talking</td>
<td>Normal</td>
<td>Intermittent slurring or nasal speech</td>
<td>Constant slurring or nasal, but can be understood</td>
<td>Difficult to understand speech</td>
<td></td>
</tr>
<tr>
<td>2. Chewing</td>
<td>Normal</td>
<td>Fatigue with solid food</td>
<td>Fatigue with soft food</td>
<td>Gastric tube</td>
<td></td>
</tr>
<tr>
<td>3. Swallowing</td>
<td>Normal</td>
<td>Rare episode of choking</td>
<td>Frequent choking necessitating changes in diet</td>
<td>Gastric tube</td>
<td></td>
</tr>
<tr>
<td>4. Breathing</td>
<td>Normal</td>
<td>Shortness of breath with exertion</td>
<td>Shortness of breath at rest</td>
<td>Ventilator dependence</td>
<td></td>
</tr>
<tr>
<td>5. Impairment of ability to brush teeth or comb hair</td>
<td>None</td>
<td>Extra effort, but no rest periods needed</td>
<td>Rest periods needed</td>
<td>Cannot do one of these functions</td>
<td></td>
</tr>
<tr>
<td>6. Impairment of ability to arise from a chair</td>
<td>None</td>
<td>Mild, sometimes uses arms</td>
<td>Moderate, always uses arms</td>
<td>Severe, requires assistance</td>
<td></td>
</tr>
<tr>
<td>7. Double vision</td>
<td>None</td>
<td>Occurs, but not daily</td>
<td>Daily, but not constant</td>
<td>Constant</td>
<td></td>
</tr>
<tr>
<td>8. Eyelid droop</td>
<td>None</td>
<td>Occurs, but not daily</td>
<td>Daily, but not constant</td>
<td>Constant</td>
<td></td>
</tr>
</tbody>
</table>

MG-ADL score total (items 1-8)=

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
### Quantitative Myasthenia Gravis (QMG) Score

<table>
<thead>
<tr>
<th>Test Item</th>
<th>Grade</th>
<th>None</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double vision on lateral gaze (secs)</td>
<td></td>
<td>61</td>
<td>11-60</td>
<td>1-10</td>
<td>Spontaneous</td>
<td></td>
</tr>
<tr>
<td>Ptosis (upward gaze)</td>
<td></td>
<td>61</td>
<td>11-60</td>
<td>1-10</td>
<td>Spontaneous</td>
<td></td>
</tr>
<tr>
<td>Facial muscles</td>
<td>Normal</td>
<td>Complete, weak, some resistance</td>
<td>Complete without resistance</td>
<td>Incomplete</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swallowing 4 oz water</td>
<td>Normal</td>
<td>Minimal coughing or throat clearing</td>
<td>Severe coughing/choking or nasal congestion</td>
<td>Cannot swallow (test not attempted)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speech after counting aloud from 1 to 50 (onset of dysarthria)</td>
<td>None at 50</td>
<td>Dysarthria at 30-49</td>
<td>Dysarthria at 10-29</td>
<td>Dysarthria at 9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right arm outstretched (90 degrees sitting), seconds</td>
<td>240</td>
<td>90-239</td>
<td>10-89</td>
<td>0-9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left arm outstretched (90 degrees sitting), seconds</td>
<td>240</td>
<td>90-239</td>
<td>10-89</td>
<td>0-9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forced Vital Capacity</td>
<td>≥80</td>
<td>65-79</td>
<td>50-64</td>
<td>≤50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rt-hand grip, kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>≥45</td>
<td>15-44</td>
<td>5-14</td>
<td>0-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>≥30</td>
<td>10-29</td>
<td>5-9</td>
<td>0-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lt-hand grip, kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
<th>15-34</th>
<th>5-14</th>
<th>0-4</th>
<th>5-9</th>
<th>0-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head lifted (45</td>
<td>120</td>
<td>&gt;25</td>
<td>30-119</td>
<td>1-29</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>degrees supine),</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>seconds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right leg</td>
<td>100</td>
<td>100</td>
<td>31-99</td>
<td>1-30</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>outstretched (45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>degrees supine),</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>seconds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left leg</td>
<td>100</td>
<td>100</td>
<td>31-99</td>
<td>1-30</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>outstretched (45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>degrees supine),</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>seconds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total QMG Score: 0

**Background/Overview**

Vyvgart is a first-in-class human immunoglobulin G1 (IgG1) antibody fragment indicated for the treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies. It binds to the neonatal Fc receptor (FcRn) causing the antibodies to stay in circulation and preventing FcRn from recycling IgG back into the blood. This leads to a reduction in the overall levels of IgG, including the abnormal AChR antibodies that are present in most patients with generalized myasthenia gravis. Vyvgart is administered as a 10 mg/kg intravenous infusion over 1 hour once weekly for 4 weeks. In patients weighing 120 kg or more, the recommended dose is 1200 mg per infusion. If subsequent treatment cycles are needed (determined based on clinical evaluation), they should be initiated no sooner than 50 days from the start of the previous treatment cycle. It should be noted that this drug causes a reduction in IgG levels, so immunization with live-attenuated or live vaccines is not recommended during treatment. If indicated, these vaccines should be administered prior to initiation of a Vyvgart treatment cycle.

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles. The hallmark of the condition is muscle weakness that worsens after periods of activity and improves after periods of rest. Certain muscles such as those that control eye and eyelid
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

movement, facial expression, chewing, talking, and swallowing are often involved in the disorder; however, the muscles that control breathing and neck and limb movements may also be affected. Acquired myasthenia gravis results from the binding of autoantibodies to components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). However, antibodies to other proteins, such as the muscle-specific kinase (MuSK) protein, can also lead to impaired transmission at the neuromuscular junction. Myasthenia gravis most commonly occurs in young adult women (<40 years of age) and older men (>60 years of age), but it can occur at any age, including childhood. The incidence ranges from 0.3 to 2.8 per 100,000, and it is estimated to affect more than 700,000 people worldwide. Various clinical scoring systems are available to assess the severity of disease and include the Myasthenia Gravis Foundation of America (MGFA) clinical classification system, Myasthenia Gravis Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG) test.

Medications to treat myasthenia gravis include anticholinesterase agents (e.g., pyridostigmine), which slow the breakdown of acetylcholine at the neuromuscular junction and thereby improve neuromuscular transmission and increase muscle strength. Immunosuppressive drugs improve muscle strength by suppressing the production of abnormal antibodies and may include prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Plasmapheresis and intravenous immunoglobulin (IVIG) may be options in severe cases to remove the destructive antibodies; however, their effectiveness frequently lasts only a few weeks to months. Additionally, the Food and Drug Administration (FDA) recently approved eculizumab (Soliris®)1 and ravulizumab (Ultomiris™)2, both complement inhibitors, for the treatment of generalized myasthenia gravis. Although Soliris, Ultomiris, and Vyvgart are the only agents with FDA approval for the condition, the other agents have been used off-label and are still recommended as first-line therapy in clinical practice guidelines. Available guidelines have not been updated to address Vyvgart.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

Vyvgart was approved in December 2021 for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The efficacy of Vyvgart for the treatment of generalized myasthenia gravis in adults who are AChR antibody positive was established in a 26-week, multicenter, randomized, double-blind, placebo-controlled trial. Included patients had a Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV, MG-ADL total score of ≥5, and were on a stable dose of myasthenia gravis therapy prior to screening that included acetylcholinesterase (AChE) inhibitors, steroids, or NSISTs, either in combination or alone. Additionally, patients had IgG levels of at least 6 g/L. A total of 167 patients were enrolled and were randomized to receive either Vyvgart 10 mg/kg (1200 mg for those weighing 120 kg or more) (n=84) or placebo (n=83). At baseline, over 80% of patients in each group received AChE inhibitors, over 70% in each group received steroids, and approximately 60% in each treatment group received NSISTs, at stable doses.

The efficacy of Vyvgart was measured using the Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) scale, which assesses the impact of generalized myasthenia gravis on daily functions of 8 signs or symptoms that are typically affected in the condition. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. A total score ranges from 0 to 24, with the higher scores indicating more impairment. In this study, an MG-ADL responder was defined as patient with a 2-point or greater reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after the last infusion of the cycle. The primary efficacy endpoint was the comparison of the percentage of MG-ADL responders during the first treatment cycle between treatment groups in the AChR-Ab positive population. A statistically significant difference favoring Vyvgart was observed in the MG-ADL responder rate during the first treatment cycle [67.7% in the Vyvgart-treated group vs 29.7% in the placebo-treated group (p<0.0001)].
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

References

Policy History
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022
08/04/2022 Medical Policy Committee review
08/10/2022 Medical Policy Implementation Committee approval. New policy.
Next Scheduled Review Date: 08/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)®, copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT.
efgartigmod alfa (Vyvgart™)

Policy #  00790
Original Effective Date:  09/12/2022
Current Effective Date:  09/12/2022

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No code</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J9332</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>G70-G70.01</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.
efgartigimod alfa (Vyvgart™)

Policy # 00790
Original Effective Date: 09/12/2022
Current Effective Date: 09/12/2022

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.